CARDIOLOGY / LETTER TO THE EDITOR
Long-term outcome of repeated septal reduction therapy after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: insight from the Euro-ASA registry
 
More details
Hide details
1
Department of Cardiology, Second Medical School, Charles University, University Hospital Motol, Prague, Czech Republic
2
Department of Cardiology, Heart and Diabetes Centre NRW, Ruhr-University Bochum, Bad Oyenhausen, Germany
3
Department of Cardiology, St. Antonius Hospital Nieuwegein, Nieuwegein, the Netherlands
4
Institute of Cardiovascular Medicine and Science, Liverpool Heart and Chest Hospital, Liverpool, England
5
Cardiocentre Podlesí, Třinec, Czech Republic
6
First Department of Internal Medicine/Cardioangiology, International Clinical Research Centre, St. Anne’s University Hospital and Masaryk University, Brno, Czech Republic
7
Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
8
Department of Cardiology, Gentofte Hospital, Copenhagen University Hospital, Hellerup, Denmark
9
Department of Internal Medicine, Juliusspital Wuerzburg, Germany
10
Unit for Inherited Cardiac Diseases, Department of Cardiology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
Submission date: 2018-03-27
Final revision date: 2018-05-21
Acceptance date: 2018-05-25
Online publication date: 2020-08-10
Publication date: 2020-08-06
 
Arch Med Sci 2020;16(5):1239–1242
 
KEYWORDS
TOPICS
ABSTRACT
Aim: The aim of this study was to assess the long-term outcomes of patients who underwent repeated septal reduction therapy after a first alcohol septal ablation. Methods and Results: We evaluated consecutive patients who underwent ASA (n=1385) and identified 145 (10%) patients who later on underwent repeated septal reduction therapy. The mean clinical follow-up period was 6.5±4.1 years. Patients who required repeated septal reduction therapy had a higher left ventricular outflow gradient and a thicker interventricular septum at baseline (both p<0.01), but the long-term occurrence of major cardiovascular adverse events was similar in both groups (p=0.17). The group of patients who underwent repeated treatment had a higher number of pacemakers (26% vs. 16%; p<0.01). Conclusions: Repeated septal reduction after the initial ASA was not associated with greater risk of cardiovascular adverse events in the long-term follow-up. However, these patients required pacemaker implantation more often.
eISSN:1896-9151
ISSN:1734-1922